Answers are grounded in this paper and cite their sources.
Idiopathic pulmonary fibrosis is a progressive fibrosing interstitial lung disease for which there is no known cure. Currently available therapeutic options have been shown at best to slow the progression of the disease and thus there remains an urgent unmet need to identify new therapies. In this article, we will discuss the mechanisms of action, pre-clinical and clinical trial data surrounding inhibitors of the autotaxin-lysophosphatidic acid axis, which show promise as emerging novel therapies for fibrotic lung disease.
No takes yet. Share an insight, caveat, or question.
Zulfikar et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: